**Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer**

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1634/theoncologist.2015-0502</td>
</tr>
<tr>
<td>Accessed</td>
<td>August 27, 2017 6:34:34 PM EDT</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:27320318">http://nrs.harvard.edu/urn-3:HUL.InstRepos:27320318</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>

*(Article begins on next page)*
Clinical Trial Results

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer

NEERAJ AGARWAL, JEAN-PASCAL MACHIELS, CRISTINA SUÁREZ, NANCY LEWIS, MICHAELA HIGGINS, KARI WISINSKI, AHMAD AWADA, MICHELA MAUR, MARK STEIN, ANDY HWANG, REBECCA MOSHER, ERNESTO WASSERMAN, GANG WU, HEFEI ZHANG, RENATA ZIEBA, MOHAMED ELMELIEGY

aHuntsman Cancer Institute, Division of Medical Oncology, Department of Medicine, University of Utah, Salt Lake City, Utah, USA; bRoi Albert II Institute, Medical Oncology Service, University Clinic Saint Luc and Institute of Experimental and Clinical Research (Pôle Molecular Imaging, Radiotherapy & Oncology), Catholic University of Louvain, Brussels, Belgium; cVall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain; dThomas Jefferson University, Philadelphia, Pennsylvania, USA; eHarvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, USA; fUniversity of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA; gJules Bordet Institute, Brussels, Belgium; hOncology Unit, Department of Oncology, Hematology and Respiratory Disease, University Hospital Policlinico of Modena, Modena, Italy; iRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA; jNovartis Pharmaceutical Corporation, East Hanover, New Jersey, USA

Access the full results at: Agarwal-15-502.theoncologist.com

Author Summary

Lessons Learned

- Despite evidence for a role for prolactin signaling in breast and prostate tumorigenesis, a prolactin receptor-binding monoclonal antibody has not produced clinical efficacy.
- Increased serum prolactin levels may be a biomarker for prolactin receptor inhibition.
- Results from the pharmacokinetic and pharmacodynamics (PD) studies suggest that inappropriately long dosing intervals and insufficient exposure to LFA102 may have resulted in lack of antitumor efficacy.
- Based on preclinical data, combination therapy of LFA102 with those novel agents targeting hormonal pathways in metastatic castration-resistant prostate cancer and metastatic breast cancer is promising.
- Given the PD evidence of prolactin receptor blockade by LFA102, this drug has the potential to be used in conditions such as hyperprolactinemia that are associated with high prolactin levels.

Abstract

Background. Prolactin receptor (PRLR) signaling is implicated in breast and prostate cancer. LFA102, a humanized monoclonal antibody (mAb) that binds to and inhibits the PRLR, has exhibited promising preclinical antitumor activity.

Methods. Patients with PRLR-positive metastatic breast cancer (mBC) or metastatic castration-resistant prostate cancer (mCRPC) received doses of LFA102 at 3–60 mg/kg intravenously once every 4 weeks. Objectives were to determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) to investigate the safety/tolerability of LFA102 and to assess pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity.

Results. A total of 73 patients were enrolled at 5 dose levels. The MTD was not reached because of lack of dose-limiting toxicities. The RDE was established at 60 mg/kg based on PK and PD analysis and safety data. The most common all-cause adverse events (AEs) were fatigue (44%) and nausea (33%) regardless of relationship. Grade 3/4 AEs reported to be related to LFA102 occurred in 4% of patients. LFA102 exposure increased approximately dose proportionally across the doses tested. Serum prolactin levels increased in response to LFA102 administration, suggesting its potential as a biomarker for PRLR inhibition. No antitumor activity was detected.

Conclusion. Treatment with LFA102 was safe and well tolerated, but did not show antitumor activity as monotherapy at the doses tested. The Oncologist 2016;21:535–536

ClinicalTrials.gov Identifier: NCT01338831
Sponsor: Novartis Pharmaceuticals Corporation
Principal Investigator: Neeraj Agarwal
IRB Approved: Yes
DISCUSSION

Prolactin, a pituitary-derived polypeptide hormone, is implicated in breast and prostate tumorigenesis. Expression of the PRLR has been confirmed in breast and prostate cancers. This phase I study evaluated LFA102 in 73 patients with PRLR-positive MBC or mCRPC, treated at doses of 3–60 mg/kg. During dose escalation, LFA102 demonstrated favorable safety and tolerability at all doses. No dose-limiting toxicities (DLTs) occurred; therefore, the MTD was not reached, although the RDE was established at 60 mg/kg based on safety, PK, and PD data supported by Bayesian logistic regression modeling. Dose proportionality analysis showed that serum LFA102 concentrations were measured up to day 28 of cycle 1 via dense sampling followed by trough concentration measurement in subsequent cycles. Concentration-time profiles show biexponential disposition typical for monoclonal antibodies. \( C_{\text{max}} \) and \( AUC_{\text{last}} \) increased in a relatively proportional manner with increasing LFA102 doses.

Abbreviations: \( AUC_{\text{last}} \), area under the last measurable concentration; \( C_{\text{max}} \), maximum concentration observed.

Impractical in patients, our study used serum prolactin levels as a surrogate marker for PRLR inhibition. A sixfold change in serum prolactin levels from baseline was observed in patients treated with LFA102 60 mg/kg, indicative of inhibition of PRLR and ruling out poor target binding as causing lack of efficacy (Fig. 2). Other potential explanations for the lack of LFA102 efficacy include that prolactin may not be an oncogenic driver in breast and prostate cancer in humans, unforeseen compensatory modulation of downstream signaling pathways in response to PRLR inhibition, or upregulation of other tumorigenic signaling pathways that compensate for PRLR inhibition. Nevertheless, preclinical data show that letrozole potentiates the efficacy of LFA102 when administered in combination in a rat mammary cancer model. Therefore, although LFA102 monotherapy may not show antitumor activity, it may have potential for treating prolactin-dependent tumors in combination with other recently approved, novel hormonal pathway targeting agents in MBC and mCRPC. Furthermore, given the PD evidence of prolactin receptor blockade by LFA102, this drug has the potential to be used in conditions such as hyperprolactinemia that are associated with high prolactin levels.

Author disclosures available online.

**EDITOR’S NOTE:** See the related commentary, “Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer,” by Ciara C. O’Sullivan and Susan E. Bates on page 523 of this issue.